IDO1 and gastric cancer: They collected dynamic plasma samples from 102 GC patients who received ICIs and screened two EV-derived proteins, namely, inducible T-cell co-stimulator (EV-ICOS) and indoleamine 2,3-dioxygenase 1 (EV-IDO1), to prognosticate the development of irAEs [124].